Perhaps Sanofi delayed but with the promise of an accelerated ramp schedule. Why?
Hikma had issues with the FDA. They also were forced to divest some of their drugs because of anti-competitive pressures:
"The Federal Trade Commission will require generic drug marketer Hikma Pharmaceuticals PLC to divest its rights and interests in five generic injectable pharmaceuticals, as part of a settlement resolving charges that Hikma’s $5 million acquisition of the rights to various drug products and related assets from Ben Venue Laboratories, Inc. would likely be anticompetitive."
